LifeStance Health Group, Inc. (LFST) Form 10-Q — Aug 6, 2026
LifeStance Health reported Q2 2026 revenue of $435.4 million, up 26% year over year, and swung to net income of $23.6 million ($0.06 diluted EPS) from a $3.8 million net loss in the year-ago quarter, while Adjusted EBITDA nearly doubled to $66.0 million from $34.0 million. Growth was driven by a net increase of 834 clinicians to 8,542 employed clinicians, 2.6 million patient visits in the quarter, and modest payor rate increases. First-half operating cash flow reached $133.0 million, and the company repurchased 13.0 million shares for $97.6 million in the first half, leaving only about $2.8 million remaining on its $100 million buyback authorization.
Key figures
- Eps
- 0.06
- Revenue
- 435354000
- Net Income
- 23612000
- Total Debt
- 275500000
- Revenue Yoy
- 26%
- Cash Position
- 225943000
- Shares Outstanding
- 382055609
- Six month eps
- 0.1
- Center margin q2
- 153041000
- Buyback remaining
- 2800000
- Patient visits q2
- 2.6 million
- Revenue growth q2
- 26%
- Six month revenue
- 838830000
- Adjusted ebitda q2
- 66042000
- Clinicians employed
- 8542
- Six month net income
- 37855000
- Buyback authorization
- 100000000
- Net clinician increase
- 834
- Six month revenue growth
- 24%
- Operating lease obligations
- 239100000
- Repurchases six months shares
- 13000000
- Operating cash flow six months
- 133021000
- Repurchases six months dollars
- 97625000
- Principal stockholders ownership
- 35.4%
- Acquisitions aggregate consideration
- 13072000
Price after filing
Close on the filing date to close N calendar days later (from $10.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.